Amgen Inc.
$346.69
▲
0.5%
2026-04-22 10:12:13
www.amgen.com
NMS: AMGN
Explore Amgen Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$187.08 B
Current Price
$346.69
52W High / Low
$391.29 / $261.43
Stock P/E
24.37
Book Value
$16.07
Dividend Yield
2.84%
ROCE
13.95%
ROE
1.06%
Face Value
—
EPS
$14.23
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
31,500
Beta
0.47
Debt / Equity
640.27
Current Ratio
1.14
Quick Ratio
0.9
Forward P/E
15.09
Price / Sales
5.15
Enterprise Value
$235.53 B
EV / EBITDA
14.17
EV / Revenue
6.41
Rating
Buy
Target Price
$351.1
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Strong operating margin profile.
- Net margin remains healthy.
- Meaningful dividend yield is available.
Cons
- Leverage is relatively high.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Merck & Co., Inc. | $112.83 | 15.49 | $278.33 B | 2.9% | 20.37% | 36.88% | $125.14 / $73.31 | $21.26 |
| 2. | Nasus Pharma Ltd. | $2.86 | — | $19.29 M | — | -172.62% | 2637.84% | $9.99 / $1.98 | $0.31 |
| 3. | Novo Nordisk A/S | $39.12 | 10.82 | $131.02 B | 4.54% | 39.01% | 60.7% | $533.4 / $224.25 | $6.83 |
| 4. | Medicus Pharma Ltd. | $0.34 | — | $13.54 M | — | -27863.04% | -29.81% | $8.94 / $0.29 | $-0 |
| 5. | Pfizer Inc. | $26.9 | 19.83 | $152.79 B | 6.25% | 10.17% | 8.89% | $28.75 / $21.87 | $15.21 |
| 6. | MIRA Pharmaceuticals, Inc. | $1.12 | — | $47.06 M | — | -100.98% | -1.66% | $2.45 / $0.83 | $0.25 |
| 7. | Eli Lilly and Company | $921 | 40.12 | $868.52 B | 0.75% | 38.44% | 1.01% | $1,133.95 / $623.78 | $29.66 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 9.87 B | 9.56 B | 9.18 B | 8.15 B | 9.09 B |
| Operating Profit | 2.72 B | 2.53 B | 2.66 B | 1.18 B | 2.31 B |
| Net Profit | 1.33 B | 3.22 B | 1.43 B | 1.73 B | 627 M |
| EPS in Rs | 2.47 | 5.97 | 2.66 | 3.21 | 1.16 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 36.75 B | 33.42 B | 28.19 B | 26.32 B |
| Operating Profit | 9.08 B | 7.26 B | 7.9 B | 9.57 B |
| Net Profit | 7.71 B | 4.09 B | 6.72 B | 6.55 B |
| EPS in Rs | 14.3 | 7.59 | 12.46 | 12.15 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 90.59 B | 91.84 B | 97.15 B | 65.12 B |
| Total Liabilities | 81.93 B | 85.96 B | 90.92 B | 61.46 B |
| Equity | 8.66 B | 5.88 B | 6.23 B | 3.66 B |
| Current Assets | 29.06 B | 29.03 B | 30.33 B | 22.19 B |
| Current Liabilities | 25.49 B | 23.1 B | 18.39 B | 15.69 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 9.96 B | 11.49 B | 8.47 B | 9.72 B |
| Investing CF | -1.94 B | -1.05 B | -26.2 B | -6.04 B |
| Financing CF | -10.86 B | -9.41 B | 21.05 B | -4.04 B |
| Free CF | 8.1 B | 10.39 B | 7.36 B | 8.79 B |
| Capex | -1.86 B | -1.1 B | -1.11 B | -936 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 18.57% | 7.09% | — | — |
| Earnings Growth % | -39.11% | 2.52% | — | — |
| Profit Margin % | 12.24% | 23.83% | 24.89% | — |
| Operating Margin % | 21.71% | 28.01% | 36.34% | — |
| Gross Margin % | 61.53% | 70.02% | 75.66% | — |
| EBITDA Margin % | 39.96% | 52.5% | 46.23% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-02-13 | $2.52 |
| 2025-11-21 | $2.38 |
| 2025-08-22 | $2.38 |
| 2025-05-16 | $2.38 |
| 2025-02-14 | $2.38 |
Stock Splits
No stock split history available.